-47.4%
NKE vs GSK
+31.2%
-78.6%
-47.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.0% | -1.9% | +1.0% | -0.4% |
| 7D | -2.0% | -1.8% | -0.2% | -1.5% |
| 30D | -8.6% | -2.2% | -6.4% | -8.0% |
| 3M | -11.0% | -1.8% | -9.2% | -10.6% |
| 6M | -33.2% | -10.6% | -22.6% | -31.5% |
| YTD | -38.1% | +4.4% | -42.6% | -39.0% |
| 1Y | -47.4% | +30.4% | -77.8% | -51.5% |
| All | -47.4% | +31.2% | -78.6% | -51.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling